PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24339712-1	2013	Treatment with interferon beta (IFN-beta) induces the production of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in patients with multiple sclerosis (MS).	babs	88-92	interferon beta 1	Homo sapiens	15-30	
24339712-1	2013	Treatment with interferon beta (IFN-beta) induces the production of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in patients with multiple sclerosis (MS).	babs	88-92	interferon beta 1	Homo sapiens	32-40	
24339712-4	2013	The presence of BAbs was studied in serum samples from 124 MS patients using one of these IFN-beta medications by ELISA.	babs	16-20	interferon beta 1	Homo sapiens	90-98	
22564111-9	2012	CONCLUSIONS: High correlation is demonstrated between the results obtained by the three methods, and we suggest the possibility of using ELISA measurements of BAbs to identify patients with high titres of anti-IFN-beta antibodies that block the biological response to IFN-beta.	babs	159-163	interferon beta 1	Homo sapiens	210-218	
22564111-9	2012	CONCLUSIONS: High correlation is demonstrated between the results obtained by the three methods, and we suggest the possibility of using ELISA measurements of BAbs to identify patients with high titres of anti-IFN-beta antibodies that block the biological response to IFN-beta.	babs	159-163	interferon beta 1	Homo sapiens	268-276	
19117201-1	2009	Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in a percentage of patients.	babs	116-120	interferon beta 1	Homo sapiens	0-21	
17889376-5	2007	We further identified a predictive relationship between positive BAbs levels and NAbs activity in patients treated with IFNbeta-1a products, but not those treated with IFNbeta-1b.	babs	65-69	interferon beta 1	Homo sapiens	120-127	
15015010-7	2004	Over the course of the study, 83% of patients developed BAbs to IFNbeta-1b, 13% to IM IFNbeta-1a, and 47 % to SC IFNbeta-1a.	babs	56-60	interferon beta 1	Homo sapiens	64-71	
15015010-13	2004	These findings demonstrate that high titers of both BAbs and NAbs reduce the clinical efficacy of IFNbeta in patients with RRMS, which is important for the long-term efficacy of these drugs.	babs	52-56	interferon beta 1	Homo sapiens	98-105	
15264110-1	2004	Treatment of multiple sclerosis (MS) with interferon beta (IFNbeta) can be associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs).	babs	130-134	interferon beta 1	Homo sapiens	42-57	
15264110-1	2004	Treatment of multiple sclerosis (MS) with interferon beta (IFNbeta) can be associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs).	babs	130-134	interferon beta 1	Homo sapiens	59-66	
15264110-2	2004	NAbs are a subset of BAbs that prevent IFNbeta from effectively binding to or activating its receptor, thereby blocking its biologic effects and inhibiting its therapeutic effects.	babs	21-25	interferon beta 1	Homo sapiens	39-46